Cassava Sciences Inc (SAVA)
$10.08
0.00 (0.00%)
SAVA Stock Quote Delayed 30 Minutes
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning!
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
423.06M
PE Ratio
-16.00
EPS
-0.63
Volume (Avg. Vol.)
558
Day's Range
-
52-Week Range
$8.79 - $32.10
Dividend & Yield
N/A (N/A)
SAVA Stock Predictions, Articles, and Cassava Sciences Inc News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investor! Wednesday starts with a breakdown of the biggest pre-market stock movers for traders to keep an eye on!
Short Squeeze Stocks: BBAI, MMAT and 3 Others Experts Think Are Ready to Pop
Short squeeze stocks continue to be of interest to retail traders looking to pump up shares while pushing hedge funds out of a company.
Cassava Sciences May Be Heading Below $10 Per Share
Cassava Sciences is facing criticism around its lead drug candidate. If that drug doesn't work, SAVA stock has a lot farther left to fall.
Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms
Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point.
Take Full Advantage of Weakness in Cassava Sciences Stock
Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer’s treatment, it could see $140 again.
Cassava Sciences Is a Worthwhile Bet to Consider
FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up.
The Crowd Has Wisely Soured on Cassava Sciences Stock
As perceptions rise that its flagship drug candidate won't make it to market, steer clear of SAVA stock.
Why Is Cassava Sciences (SAVA) Stock Down Today?
SAVA stock is tumbling after The New York Times reported that multiple experts are skeptical about Cassava's data and its main theory.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday!
Cassava Sciences Is Worth Considering After Hitting Its Latest Trough
The company has no debt and is cash rich. If it receives FDA approval for its Simufilam drug, the SAVA stock price will catapult.
Why Is Cassava Sciences (SAVA) Stock Down Today?
Cassava Sciences (SAVA) stock is falling on Tuesday as investors react to a recent fireside chat held by CEO Remi Barbier.
Risk-on Biotech Investors Should Buy Cassava Sciences
SAVA stock is volatile but worthwhile after opinion shifts in its favor. Remember, it has a blockbuster Alzheimer's drug nearing launch.
Keep Risk in Mind With Cassava Sciences Stock, but Don’t Dismiss Upside Potential
If you can stomach the risk and have experience investing in clinical stage biotech plays, SAVA stock remains an interesting situation. After its recent weakness, you may find now to be the right time to initiate a position.
Cassava Sciences Is in a Bleak Midwinter Waiting for Spring and Better Days
SAVA stock is driven by updates on clinical Phase 3 trials and lots of irrationality. Meanwhile, an FDA approval may take quite some time.
Why Cassava Sciences Is Still a High-Risk Play
As it's not set in stone that Cassava Sciences will be able to bring simulfilam to market, you should approach SAVA stock cautiously.
Does Cassava Sciences and Its Alzheimer’s Drug Really Have What It Takes?
Can Cassava Sciences' Simufilam drug really treat Alzheimer's? Who really knows. SAVA stock is pure speculation either way.
Keep an Eye on $60 as a Target Price for Cassava Sciences
As long as you're using a moderate position size, it's fine to hold SAVA stock as it has a tendency to move fast and far from time to time.
The End Result May Be Worth the Wait With Cassava Sciences Stock
SAVA stock will continue to trade sideways until the moment of truth arrives for its drug candidate Simufilam.
